Unraveling the realities of vascular access: The Network 11 experience

被引:23
作者
Besarab, A [1 ]
Adams, M [1 ]
Amatucci, S [1 ]
Bowe, D [1 ]
Deane, J [1 ]
Ketchen, K [1 ]
Reynolds, K [1 ]
Tello, A [1 ]
机构
[1] Upper Midwest Inc, Renal Network ESRD Network 11, St Paul, MN 55114 USA
来源
ADVANCES IN RENAL REPLACEMENT THERAPY | 2000年 / 7卷 / 04期
关键词
vascular access; hemodialysis; arteriovenous fistula; graft; catheter; referral;
D O I
10.1053/jarr.2000.18440
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Arteriovenous (AV) fistulae are well recognized as the preferred vascular access for hemodialysis, yet national data show that only 23% of patients used an AV fistula in 1997. To identify barriers to the placement of native AV fistulae, the Renal Network of the Upper Midwest, Inc. (End-Stage Renal Disease [ESRD] Network 11) initiated a vascular access project to look at the process of referral for patients beginning hemodialysis in the first 6 months of 1999. Of these patients, 63% began hemodialysis with a catheter as the only access, 22% had an AV fistula placed (but only 14% used an AV fistula for their first dialysis treatment), and 15% began with a graft. About 40% of patients were referred to a nephrologist less than 1 month before dialysis, allowing little chance for permanent access placement. Yet 27% of patients used a catheter on the first hemodialysis treatment and were seen by a nephrologist more than 1 month before starting dialysis, indicating the presence of an opportunity to improve. At 6 months after initiation of dialysis, 25% of patients who began dialysis using a catheter were using an AV fistula and 35% were using a graft. Network 11 plans to use this information to promote early referral of patients to a nephrologist and subsequent prompt referral of such patients to a vascular surgeon. Other activities to improve vascular access management are also indicated. (C) 2000 by the National Kidney Foundation, Inc.
引用
收藏
页码:S65 / S70
页数:6
相关论文
共 13 条
[1]  
BESARAB A, 1996, J AM SOC NEPHROL, V9, P1403
[2]  
*CDC, 1999, NAT SURV DIAL ASS DI
[3]   CANADIAN HEMODIALYSIS MORBIDITY STUDY [J].
CHURCHILL, DN ;
TAYLOR, DW ;
COOK, RJ ;
LAPLANTE, P ;
BARRE, P ;
CARTIER, P ;
FAY, WP ;
GOLDSTEIN, MB ;
JINDAL, K ;
MANDIN, H ;
MCKENZIE, JK ;
MUIRHEAD, N ;
PARFREY, PS ;
POSEN, GA ;
SLAUGHTER, D ;
ULAN, RA ;
WERB, R .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (03) :214-234
[4]   THE USE OF HEALTH-CARE FINANCING ADMINISTRATION DATA FOR THE DEVELOPMENT OF A QUALITY IMPROVEMENT PROJECT ON THE TREATMENT OF ANEMIA [J].
EGGERS, PW ;
GREER, J ;
JENCKS, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 24 (02) :247-254
[5]  
Feldman HI, 1996, J AM SOC NEPHROL, V7, P523
[6]  
Henry ML., 1991, VASCULAR ACCESS HEMO, P145
[7]  
HOOD SA, 1995, ASAIO J, V41, pM422, DOI 10.1097/00002480-199507000-00044
[8]   Excess morbidity in patients starting uremia therapy without prior care by a nephrologist [J].
Ifudu, O ;
Dawood, M ;
Homel, P ;
Friedman, EA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (06) :841-845
[9]  
*NAT KIDN FDN, 1997, AM J KIDNEY DIS S, V30, pS154
[10]  
PEREIRA B, 1998, AM J KIDNEY DIS S, V32, pS190